TCF — Theracryf Share Price
Last trade - 00:00- £4.51m
- £0.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.76 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.59% | ||
| Return on Equity | -46.71% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.19 | n/a | 0.44 | 0.4 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Directors
- Barry Clare CHM (67)
- Huw Jones CEO (61)
- Richard Moulson CFO
- Glen Clack OTH
- Susan Foden NED (67)
- Alan Barge NED (61)
- Susan Clement-Davies NED
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- October 2nd, 2014
- Public Since
- October 21st, 2015
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 2,148,963,739
- Address
- Suite 24G13 - Block 24 Alderley Park, NETHERTON, SK10 4TG
- Web
- https://theracryf.com/
- Phone
- +44 1625315090
- Auditors
- RSM UK Audit LLP
Latest News for TCF
Upcoming Events for TCF
TheraCryf PLC at BioSeed North
TheraCryf PLC at BioEurope
TheraCryf PLC at ShareSoc Growth Company Seminar
TheraCryf PLC at Mello London
TheraCryf PLC at Jefferies Global Healthcare Conference
Half Year 2026 TheraCryf PLC Earnings Release
Similar to TCF
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 23:41 UTC, shares in Theracryf are trading at 0.21p. This share price information is delayed by 15 minutes.
Shares in Theracryf last closed at 0.21p and the price had moved by -68.89% over the past 365 days. In terms of relative price strength the Theracryf share price has underperformed the FTSE All Share Index by -71.88% over the past year.
The overall consensus recommendation for Theracryf is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreTheracryf does not currently pay a dividend.
Theracryf does not currently pay a dividend.
Theracryf does not currently pay a dividend.
To buy shares in Theracryf you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 0.21p, shares in Theracryf had a market capitalisation of £4.51m.
Here are the trading details for Theracryf:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: TCF
Based on an overall assessment of its quality, value and momentum Theracryf is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Theracryf is 3.20p. That is 1423.81% above the last closing price of 0.21p.
Analysts covering Theracryf currently have a consensus Earnings Per Share (EPS) forecast of -£0.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theracryf. Over the past six months, its share price has underperformed the FTSE All Share Index by -17.01%.
As of the last closing price of 0.21p, shares in Theracryf were trading -40.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Theracryf PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.21p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Theracryf's management team is headed by:
- Barry Clare - CHM
- Huw Jones - CEO
- Richard Moulson - CFO
- Glen Clack - OTH
- Susan Foden - NED
- Alan Barge - NED
- Susan Clement-Davies - NED